PMID: 8961775Jan 1, 1996Paper

Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety

Psychopharmacology Bulletin
M ErnstA J Zametkin

Abstract

Clinical effects of high-dose and low-dose selegiline treatment were examined in 24 adults with attention deficit hyperactivity disorder (ADHD). The study used a double-blind randomized three-arm parallel-groups design with a 2-week placebo baseline followed by 6 weeks of treatment (placebo, 20 mg/day, or 60 mg/day selegiline) and then by 2 weeks of placebo post-treatment. A two-way repeated measures analysis of variance (ANOVA) showed no Drug x Time interaction and no main effect of Drug on severity of ADHD symptoms as self-rated by the subjects on the Conners Abbreviated Teacher Rating Scale (Conners ATRS). There was a significant effect of Time, indicating decreased ADHD symptom severity scores in all three groups. Selegiline treatment was not more effective than placebo. Side effects were more severe in the high-dose selegiline group than in either of the other groups. These preliminary results must be interpreted with caution because of methodological limitations in terms of sample size, patient population selection, and measurement tools.

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
M ErnstA J Zametkin
Journal of the American Academy of Child and Adolescent Psychiatry
S L KaplanB Segal
Journal of Abnormal Child Psychology
R K UllmannR L Sprague
Progress in Neuro-psychopharmacology & Biological Psychiatry
Shahin AkhondzadehHomayoun Amini
© 2021 Meta ULC. All rights reserved